Patheon announced that with an investment of $26 million it has updated sterile Pharmaceutical Development Services (PDS) suites at its Greenville, NC manufacturing site. The PDS Suites 1 and 2 provide 7,000-square-feet in GMP steriles manufacturing space.
The newly built PDS suite will manufacture sterile liquid and lyophilized drug products. It features freeze dryers and a fully integrated filling line fitted with a Restricted Access Barrier System (RABS) for sterile drug products. This suite is highly sophisticated, fully integrated and designed for products in clinical development with the ability to scale up to much larger batch sizes via Patheon’s network of commercial scale capabilities within the Greenville facility, or in Europe.
Patheon’s president of drug product and pharmaceutical services for North America, Franco Negron said that as the industry continues to innovate, customers will require even more advanced solutions, integrating development and commercial service, to meet their business needs. The increasing focus on pharma to reduce costs will lead forward-thinking companies to capitalize on their core competencies – focusing on what they do best, while strategically partnering with companies such as Patheon to deliver the expertise, customized solutions and technical capabilities to support the production of their small and large molecule products.